Skip to main content
OpenTrials

Clinical trial condition

Hyperoxaluria, Primary

Explore clinical trials studying Hyperoxaluria, Primary. Study availability and eligibility vary by location and protocol.

33 public trials 6 recruiting studies
Refine in advanced search Browse all conditions

Hyperoxaluria, Primary trial results

Completed

A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1

NCT04152200

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, +14 more
Locations
  • Clinical Trial Site Rochester, Minnesota, United States
  • Clinical Trial Site Houston, Texas, United States
  • Clinical Trial Site Garran, Australia
  • Clinical Trial Site Brussels, Belgium
View all 14 locations
View Trial Details
Completed

A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1

NCT03905694

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, +14 more
Locations
  • Clinical Trial Site Rochester, Minnesota, United States
  • Clinical Trial Site Houston, Texas, United States
  • Clinical Trial Site Lyon, France
  • Clinical Trial Site Paris, France
View Trial Details
Completed

Natural History of Patients With PH3 and a History of Stone Events

NCT04542590

Conditions
Calcinosis, Calcium Metabolism Disorders, Calculi, +22 more
Locations
  • Clinical Trial Site Boston, Massachusetts, United States
  • Clinical Trial Site New York, United States
  • Clinical Trial Site Toronto, Ontario, Canada
  • Clinical Trial Site Heidelberg, Germany
View Trial Details
Completed

Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients

NCT04555486

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, +12 more
Locations
  • Clinical Trial Site Boston, Massachusetts, United States
  • Clinical Trial Site Rochester, Minnesota, United States
  • Clinical Trial Site New York, United States
  • Clinical Trial Site Bonn, Germany
View Trial Details
Completed

Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

NCT03392896

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, +12 more
Locations
  • Boston Children's Hospital Boston, Massachusetts, United States
  • Centre d'Investigation Clinique - CIC 1407 - Hospices Civils de Lyon Bron, France
  • Universitätsklinikum Bonn-Institut für Klinische Chemie und Klinische Pharmakologie Bonn, Germany
  • University of Amsterdam Amsterdam, Netherlands
View Trial Details
Completed

A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

NCT03681184

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, +13 more
Locations
  • Clinical Trial Site San Diego, California, United States
  • Clinical Trial Site Jacksonville, Florida, United States
  • Clinical Trial Site Rochester, Minnesota, United States
  • Clinical Trial Site New York, United States
View all 17 locations
View Trial Details
Completed

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

NCT03847909

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, +16 more
Locations
  • Clinical Trial Site San Francisco, California, United States
  • Clinical Trial Site Boston, Massachusetts, United States
  • Clinical Trial Site Rochester, Minnesota, United States
  • Clinical Trial Site New York, United States
View all 28 locations
View Trial Details
Completed

An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1

NCT03350451

Conditions
AGT, Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +16 more
Locations
  • Clinical Trial Site Bordeaux, France
  • Clinical Trial Site Lyon, France
  • Clinical Trial Site Paris, France
  • Clinical Trial Site Bonn, Germany
View Trial Details
Completed

Health-related Quality of Life in Rare Kidney Stone

NCT02124395

Conditions
Adenine Phosphoribosyl Transferase Deficiency, Adenine phosphoribosyltransferase deficiency, Carbohydrate Metabolism, Inborn Errors, +19 more
Locations
  • Primary Hyperoxaluria and Dent Disease Registry - Mayo Clinic Rochester, Minnesota, United States
  • New York University School of Medicine - Cystinuria Registry New York, United States
  • APRT Registry - Landspitali Universtiy Hospital Reykjavik, Iceland
View Trial Details

Related conditions